HKD 1.01
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 1.46 Billion HKD | -17.8% |
2022 | 1.78 Billion HKD | 11.91% |
2021 | 1.59 Billion HKD | 10.35% |
2020 | 1.44 Billion HKD | -7.99% |
2019 | 1.57 Billion HKD | 6.31% |
2018 | 1.47 Billion HKD | -4.56% |
2017 | 1.54 Billion HKD | 23.31% |
2016 | 1.25 Billion HKD | 15.88% |
2015 | 1.08 Billion HKD | 14.38% |
2014 | 947.59 Million HKD | 2.31% |
2013 | 926.18 Million HKD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2023 FY | 1.46 Billion HKD | -17.8% |
2023 Q4 | 752.88 Million HKD | 0.0% |
2023 Q2 | 714.91 Million HKD | 0.0% |
2022 Q4 | 968.22 Million HKD | 0.0% |
2022 FY | 1.78 Billion HKD | 11.91% |
2022 Q2 | 817.35 Million HKD | 0.0% |
2021 FY | 1.59 Billion HKD | 10.35% |
2021 Q2 | 750.41 Million HKD | 0.0% |
2021 Q4 | 845.13 Million HKD | 0.0% |
2020 Q2 | 695.42 Million HKD | 0.0% |
2020 FY | 1.44 Billion HKD | -7.99% |
2020 Q4 | 750.49 Million HKD | 0.0% |
2019 Q2 | 871.68 Million HKD | 0.0% |
2019 Q4 | 699.77 Million HKD | 0.0% |
2019 FY | 1.57 Billion HKD | 6.31% |
2018 FY | 1.47 Billion HKD | -4.56% |
2018 Q2 | 816.26 Million HKD | 0.0% |
2017 Q2 | 743.03 Million HKD | 0.0% |
2017 Q4 | 805.65 Million HKD | 0.0% |
2017 FY | 1.54 Billion HKD | 23.31% |
2016 Q2 | 575.44 Million HKD | 0.0% |
2016 FY | 1.25 Billion HKD | 15.88% |
2016 Q4 | 680.5 Million HKD | 0.0% |
2015 Q2 | 518.18 Million HKD | 0.0% |
2015 FY | 1.08 Billion HKD | 14.38% |
2015 Q4 | 565.67 Million HKD | 0.0% |
2014 Q1 | 231.54 Million HKD | 0.0% |
2014 Q2 | 231.54 Million HKD | 0.0% |
2014 FY | 947.59 Million HKD | 2.31% |
2014 Q3 | 236.89 Million HKD | 2.31% |
2014 Q4 | 236.89 Million HKD | 0.0% |
2013 Q4 | 231.54 Million HKD | 0.0% |
2013 FY | 926.18 Million HKD | 0.0% |
2013 Q3 | 231.54 Million HKD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Pak Fah Yeow International Limited | 259.15 Million HKD | -466.372% |
Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 86.06% |
Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -2383.668% |
Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -87.248% |
Qianhai Health Holdings Limited | 961.29 Million HKD | -52.69% |
Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -39.388% |
Essex Bio-Technology Limited | 1.7 Billion HKD | 13.991% |
Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -81.41% |
PuraPharm Corporation Limited | 406.85 Million HKD | -260.763% |
SSY Group Limited | 6.46 Billion HKD | 77.289% |
JBM (Healthcare) Limited | 648.41 Million HKD | -126.367% |
China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.457% |